drugset / Trial / NCT00648570
Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the bioequivalence of Mylan's escitalopram oxalate 20 mg tablets to Forest's Lexapro® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administered under fasting conditions.
Timeline
- Start
- 2004-08
- Primary completion
- 2004-10
- Completion
- 2004-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Escitalopram | Small molecule | 20 mg | Oral |
Indications
No indication recorded.